{"classes":[{"categories":[{"measurements":[{"comment":"Could not be calculated due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"50.0","upperLimit":"NA","value":"54.0"},{"groupId":"OG001","lowerLimit":"50.0","upperLimit":"236.0","value":"56.0"},{"comment":"Could not be calculated due to insufficient number of participants with events","groupId":"OG002","lowerLimit":"58.0","upperLimit":"NA","value":"85.0"},{"groupId":"OG003","lowerLimit":"44.0","upperLimit":"97.0","value":"63.0"},{"groupId":"OG004","lowerLimit":"33.0","upperLimit":"107.0","value":"87.0"},{"comment":"Could not be calculated due to insufficient number of participants with events","groupId":"OG005","lowerLimit":"62.0","upperLimit":"NA","value":"177.0"},{"comment":"Could not be calculated due to insufficient number of participants with events","groupId":"OG006","lowerLimit":"23.0","upperLimit":"NA","value":"65.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"7"}],"units":"Participants"}],"description":"PFS was defined as the number of days between the date of the first dose of treatment of a patient and the first date of disease progression, start of a subsequent anti-cancer therapy, or death of the patient.","dispersionType":"90% Confidence Interval","groups":[{"description":"Progression-free survival (PFS) time for patients with small cell lung cancer who received 80 mg/m2 of EDO-S101 administered over 1 hour on Day 1 and 15 of each 4-week treatment cycle.","id":"OG000","title":"Tinostamustine (EDO-S101) - Phase 2 SCLC Cohort"},{"description":"Progression-free survival (PFS) time for patients with soft tissue sarcoma who received 80 mg/m2 of EDO-S101 administered over 1 hour on Day 1 and 15 of each 4-week treatment cycle.","id":"OG001","title":"Tinostamustine (EDO-S101) - Phase 2 STS Cohort"},{"description":"Progression-free survival (PFS) time for patients with triple-negative breast cancer who received 80 mg/m2 of EDO-S101 administered over 1 hour on Day 1 and 15 of each 4-week treatment cycle.","id":"OG002","title":"Tinostamustine (EDO-S101) - Phase 2 TNBC Cohort"},{"description":"Progression-free survival (PFS) time for patients with ovarian cancer who received 80 mg/m2 of EDO-S101 administered over 1 hour on Day 1 and 15 of each 4-week treatment cycle.","id":"OG003","title":"Tinostamustine (EDO-S101) - Phase 2 OC Cohort"},{"description":"Progression-free survival (PFS) time for patients with endometrial cancer who received 80 mg/m2 of EDO-S101 administered over 1 hour on Day 1 and 15 of each 4-week treatment cycle.","id":"OG004","title":"Tinostamustine (EDO-S101) - Phase 2 EC Cohort"},{"description":"Progression-free survival (PFS) time for patients with solid tumour who received 60 mg/m2 of EDO-S101 administered over 1 hour","id":"OG005","title":"Tinostamustine (EDO-S101) - Sub Study 1 (SS1)"},{"description":"Progression-free survival (PFS) time for patients with solid tumour who received 80 mg/m2 of EDO-S101 administered over 80 minutes","id":"OG006","title":"Tinostamustine (EDO-S101) - Sub Study 2 (SS2)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From patient's first dose until first documented progression/start of subsequent anti-cancer therapy/death from any cause, whichever came first, up to 26 months.","title":"Progression Free Survival (PFS) Time for Phase 2 and Sub Studies","type":"SECONDARY","unitOfMeasure":"days"}